文献速递妇产影像US

胎儿小于胎龄不同严重度分级的母体血管生成因子水平

Angiogenic factor levels across severity stages of fetal smallness with or without associated pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2026-01-08

这项前瞻性队列研究纳入604例小于胎龄单胎妊娠和424例适于胎龄对照,按严重度分为SGA及FGR I至IV期。研究发现母体sFlt-1/PlGF比值随胎儿小于胎龄严重度增加而更趋异常,且在合并子痫前期时该关联更明显。但绝对值在有无子痫前期情况下均存在较大重叠,用于判断严重度分级仍有困难。

要点

  • sFlt-1/PlGF比值>第95百分位在FGR III-IV期达62.5%,提示严重FGR时血管生成因子更异常。
  • 合并子痫前期的小于胎龄胎儿中sFlt-1/PlGF比值>第95百分位为56.9%,远高于无子痫前期者的15.4%。
  • 因绝对值重叠较大,不建议单独用sFlt-1/PlGF比值替代超声Doppler进行FGR严重度分级。

核心结论

  • 母体血清血管生成因子水平随胎儿小于胎龄严重度分期增加而更趋异常。
  • 该严重度关联在合并子痫前期时更强。
  • 血清绝对值在有无子痫前期情况下均存在较大重叠,难以用于判断胎儿小于胎龄的严重度分级。

研究设计与样本

  • 前瞻性队列研究,纳入2010年10月至2017年12月诊断胎儿小于胎龄的单胎妊娠604例。
  • 对照组为适龄单胎妊娠424例,胎儿小于胎龄定义为出生体重<第10百分位。
  • 诊断时行超声评估估测胎儿体重及UtA、UA、MCA、DV的搏动指数,并定期监测至分娩。
  • 采用酶联免疫吸附试验测定母体外周静脉血PlGF与sFlt-1浓度,并计算sFlt-1/PlGF比值。

关键影像表现/征象

  • FGR I期定义为估测胎儿体重<第3百分位或MCA-PI<第5百分位或UA-PI>第95百分位或CPR<第5百分位或UtA-PI>第95百分位。
  • FGR II期定义为脐动脉舒张末期血流消失。
  • FGR III期定义为脐动脉舒张末期血流反向或DV-PI≥第95百分位。
  • FGR IV期定义为胎心监护出现非可靠图形或DV心房血流消失/反向。

诊断标准与关键数值

  • sFlt-1/PlGF比值>第95百分位比例在AGA对照为12.7%,SGA为7.8%,FGR I期为30.8%,FGR II期为43.8%,FGR III-IV期为62.5%(P=0.0001)。
  • sFlt-1/PlGF比值的中位MoM在AGA对照为0.55(IQR,0.19-2.00),SGA为1.00(IQR,0.31-2.67),FGR I期为3.03(IQR,0.91-8.20)。
  • sFlt-1/PlGF比值的中位MoM在FGR II期为3.94(IQR,0.85-9.13),FGR III-IV期为7.32(IQR,1.44-16.29)(P=0.24)。
  • 所有小于胎龄胎儿中合并子痫前期者sFlt-1/PlGF比值>第95百分位比例为56.9%,无子痫前期者为15.4%(P<0.001)。

临床应用与阅片要点

  • 阅片和报告时可将sFlt-1/PlGF比值作为FGR严重度分级的辅助参考,而非独立诊断指标。
  • 当sFlt-1/PlGF比值明显升高时需警惕合并子痫前期的可能。
  • 超声Doppler参数仍是FGR分期的主要依据,母体血管生成因子不能替代影像学评估。
  • 在FGR分级报告中综合血管生成因子与UtA、UA、MCA、DV多普勒参数有助于风险评估。

局限性

  • 原文未报告研究设计的其他明显局限,如单中心或多中心、是否存在选择偏倚等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Angiogenic factors are elevated in fetal growth restriction (FGR), but their clinical value for assessing the severity of FGR and the potential influence of coexisting pre-eclampsia has scarcely been investigated. In this study, our aim was to investigate the profile of maternal angiogenic factors across severity stages of fetal smallness compared with controls, analyzed overall and stratified by the presence or absence of pre-eclampsia, and to investigate whether values of these angiogenic factors, such as placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and the sFlt-1/PlGF ratio, are helpful in determining the severity stage of fetal smallness.

METHODS: This was a prospective cohort study of women with a singleton pregnancy diagnosed with fetal smallness (defined as birth weight < 10th centile) (n = 604) between October 2010 and December 2017, compared with a control group of pregnant women with an appropriate-for-gestational-age (AGA) singleton fetus (defined as birth weight ≥ 10th centile) (n = 424). At diagnosis, ultrasound was performed to assess estimated fetal weight (EFW) and Doppler pulsatility indices (PI) of the uterine artery (UtA), umbilical artery (UA), fetal middle cerebral artery (MCA) and ductus venosus (DV), and these parameters were monitored regularly until delivery. Cerebroplacental ratio (CPR) was calculated as MCA-PI/UA-PI. Small fetuses were classified as: small-for-gestational age (SGA) if EFW ≥ 3rd and < 10th centile, with normal Doppler parameters; FGR Stage I if either EFW < 3rd centile, persistent MCA-PI < 5th centile, UA-PI > 95th centile, CPR < 5th centile or UtA-PI > 95th centile; FGR Stage II if there was absent end-diastolic flow in the UA; FGR Stage III if there was reversed end-diastolic flow in the UA or DV-PI ≥ 95th centile; or FGR Stage IV if there was non-reassuring cardiotocography or absent/reversed DV atrial flow. Maternal peripheral venous blood concentrations of PlGF and sFlt-1 were determined using enzyme-linked immunosorbent assay, and the sFlt-1/PlGF ratio was calculated. Linear trend of proportions was tested using the Mantel-Haenszel chi-square test.

RESULTS: Among AGA controls (n = 424), SGA (n = 192), FGR Stage I (n = 380), FGR Stage II (n = 16) and FGR Stages III-IV (n = 16) fetuses, the proportion of cases with a sFlt-1/PlGF ratio > 95th centile was 12.7%, 7.8%, 30.8%, 43.8% and 62.5%, respectively (P = 0.0001), and the median multiples of the median (MoM) values for the sFlt-1/PlGF ratio were 0.55 (interquartile range (IQR), 0.19-2.00), 1.00 (IQR, 0.31-2.67), 3.03 (IQR, 0.91-8.20), 3.94 (IQR, 0.85-9.13) and 7.32 (IQR, 1.44-16.29), respectively (P = 0.24). Pre-eclampsia was diagnosed at any time between inclusion and delivery in 1.9% of controls, 3.6% of SGA, 21.1% of FGR Stage I, 37.5% of FGR Stage II and 50.0% of FGR Stages III-IV fetuses. Among all small fetuses with vs without pre-eclampsia, the proportion of pregnancies with sFlt-1/PlGF ratio > 95th centile was 56.9% vs 15.4% (P < 0.001) and the median MoM of the sFlt-1/PlGF ratio was 8.11 (IQR, 3.83-27.09) vs 1.59 (IQR, 0.52-5.04) (P = 0.18).

CONCLUSIONS: Serum levels of angiogenic factors became more abnormal as the severity stage of fetal smallness increased. This association with severity was stronger in the presence of pre-eclampsia. However, absolute values of serum levels showed substantial overlap in both the presence and the absence of pre-eclampsia, making their use in determining the severity stage of fetal smallness challenging. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Youssef, Paolucci, Crovetto, et al. Angiogenic factor levels across severity stages of fetal smallness with or without associated pre-eclampsia. Ultrasound Obstet Gynecol. 2026. PMID: 41505741. doi:10.1002/uog.70156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。